SRR4195696
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.480
- INTERFERON_ALPHA_RESPONSE+0.310
- MYC_TARGETS_V1+0.300
- E2F_TARGETS+0.250
- DNA_REPAIR+0.220
- BILE_ACID_METABOLISM+0.200
- XENOBIOTIC_METABOLISM+0.190
- FATTY_ACID_METABOLISM+0.160
- OXIDATIVE_PHOSPHORYLATION+0.140
- SPERMATOGENESIS+0.110
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.670
- TNFA_SIGNALING_VIA_NFKB-0.540
- UV_RESPONSE_DN-0.490
- TGF_BETA_SIGNALING-0.480
- ANDROGEN_RESPONSE-0.460
- HYPOXIA-0.430
- ANGIOGENESIS-0.410
- APICAL_JUNCTION-0.410
- MYOGENESIS-0.400
- INFLAMMATORY_RESPONSE-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-GV-A6ZA-01A-12R-A33J-07 | — | — | 0.893 |
| 2 | SRR25617851 | — | B | 0.877 |
| 3 | R175 | — | — | 0.863 |
| 4 | TCGA-P3-A6SW-01A-11R-A34R-07 | — | — | 0.863 |
| 5 | 9da01737-be8f-4af5-9f8f-47bb892b6339 | — | — | 0.858 |
| 6 | SRR25617913 | — | D | 0.853 |
| 7 | TCGA-XF-AAN1-01A-31R-A42T-07 | — | — | 0.849 |
| 8 | BS_2A5R9MEJ | high-grade glioma | — | 0.849 |
| 9 | TCGA-E9-A3HO-01A-11R-A213-07 | — | B | 0.848 |
| 10 | 2d8478f6-41ac-47f5-ac3c-337af7245f5b | — | — | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.190 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.140 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.040 | Inavolisib | — uncovered |